Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT07557420 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

NMOSD
Neuromyelitis Optica Spectrum Disorder

Interventions

DRUG: Ravulizumab

Sponsor

Alexion Pharmaceuticals, Inc.